Cyprus heavily depends on imported medicine, with only 40% of authorized pharmaceutical products available locally, as outlined in a European Commission report. Notably, around 20% of these medicines come through Article 5 of Directive 2001/83/EC, addressing unique medical needs without standard marketing approvals.
Moves Toward Better Access
Efforts are underway to improve the situation in Cyprus, as well as in Malta and Ireland. Suggested strategies include simplifying drug authorization, encouraging multi-country packaging solutions, and utilizing digital platforms to overcome language barriers.
Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram
EU’s Pharma Trade Boom
Despite these challenges in smaller member states, the European Union recorded a remarkable pharmaceutical trade surplus last year—analyzing the trends shows a 13.5% increase in exports, reaching €313.4 billion while maintaining a €193.6 billion trade surplus.
Leading the export charge, Germany achieved €67.9 billion, with Ireland and Belgium following closely. Meanwhile, Germany also led imports, indicating dynamic intra-EU trade flows.
Global Trade Dynamics
The United States dominates as the EU’s top pharmaceutical trading partner, followed by Switzerland and the United Kingdom. These relationships underscore the EU’s strong global position in the pharmaceutical sector.
